Zhao Heng, Yang Haitang, Han Ke, Xu Jianlin, Yao Feng, Zhao Yang, Fan Liwen, Gu Haiyong, Shen Zhenya
Department of Cardiovascular Surgery of First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.
Division of General Thoracic Surgery, Inselspital, Bern University Hospital; Graduate School for Cellular and Biomedical Sciences; Department of Clinical Research, University of Bern, Bern, Switzerland.
Onco Targets Ther. 2017 Jan 10;10:295-302. doi: 10.2147/OTT.S122908. eCollection 2017.
The incidence of adenocarcinomas as multiple primary lung cancers (MPLCs) is increasing. How to determine the treatment strategies of MPLCs, especially second primary lung adenocarcinomas (SPLACs), and the prognostic factors associated with it are unclear.
The clinical records of patients undergoing surgery for second adenocarcinomas based on Martini-Melamed criteria between 2001 and 2014 were retrospectively reviewed. Survival rates were calculated by the Kaplan-Meier method and compared using the log-rank test. Multivariate analysis was conducted using the Cox proportional hazards model.
A total of 115 patients with SPLACs were identified based on Martini-Melamed criteria. With respect to the second resections, three subgroups with low- (adenocarcinoma in situ, n=6; minimally invasive adenocarcinoma, n=19), intermediate- (lepidic, n=9; acinar, n=40; papillary, n=23), and high-grades (solid, n=9; micropapillary, n=2; invasive mucinous, n=7) were assigned. The 5-year overall survival (OS) rates from the time of the first and the second resections were 86.5% and 69.5%, respectively. Cox multivariate analysis identified computed tomography (CT) morphology of SPLACs (ground glass opacity predominant versus solid predominant; hazard ratio [HR]=0.42; =0.036), histologic classification (same/similar vs different; HR=0.06; <0.001), pathologic stage of the primary (stage I vs II; HR=0.20; =0.015) and second tumors (stage I vs IIIa; HR=0.21; =0.002), and histologic grade of SPLACs (low- vs high-grade, HR=0.05, =0.016; intermediate- vs high-grade, HR=0.37, =0.027) as significantly favorable prognostic factors for OS.
In addition to pathologic stage of the initial tumors and histologic classification, pathologic stage and CT morphology of SPLACs were identified as predictors of survival. The histologic grade of SPLACs based on the new adenocarcinoma classification could provide additional prognostic information.
作为多原发性肺癌(MPLC)的腺癌发病率正在上升。如何确定MPLC的治疗策略,尤其是第二原发性肺腺癌(SPLAC),以及与之相关的预后因素尚不清楚。
回顾性分析2001年至2014年间根据Martini-Melamed标准接受第二次腺癌手术患者的临床记录。采用Kaplan-Meier法计算生存率,并使用对数秩检验进行比较。使用Cox比例风险模型进行多变量分析。
根据Martini-Melamed标准共确定了115例SPLAC患者。关于第二次切除,分为低级别(原位腺癌,n = 6;微浸润腺癌,n = 19)、中级别(鳞屑状,n = 9;腺泡状,n = 40;乳头状,n = 23)和高级别(实性,n = 9;微乳头状,n = 2;浸润性黏液性,n = 7)三个亚组。第一次和第二次切除时的5年总生存率(OS)分别为86.5%和69.5%。Cox多变量分析确定SPLAC的计算机断层扫描(CT)形态(磨玻璃密度影为主与实性为主;风险比[HR]=0.42;P = 0.036)、组织学分类(相同/相似与不同;HR = 0.06;P < 0.001)、原发性肿瘤(I期与II期;HR = 0.20;P = 0.015)和第二肿瘤(I期与IIIa期;HR = 0.21;P = 0.002)的病理分期以及SPLAC的组织学分级(低级别与高级别,HR = 0.05,P = 0.016;中级别与高级别,HR = 0.37,P = 0.027)为OS的显著有利预后因素。
除了初始肿瘤的病理分期和组织学分类外,SPLAC的病理分期和CT形态被确定为生存的预测因素。基于新腺癌分类的SPLAC组织学分级可提供额外的预后信息。